ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2349

Predictive Potential of Serum Metabolites Associated with Treatment Response to Interleukin -17 Inhibitors in Patients with PsA

Abigail Cave1, Sheng Han Li2, Nikita Looby3, Max Kotiyar4, Igor Jurisica5, Vathany Kulasingam6, Proton Rahman7 and Vinod Chandran8, 1Dalhousie University, Alliston, ON, Canada, 2Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada, 3Psoriatic Arthritis Program Schroeder Arthritis Institute, Toronto, Canada, 4Data Science Discovery Centre for Chronic Dsiease, Krembil Research Institute, Toronto, Canada, 5Departments of Medical Biophysics and Computer Science and Faculty of Dentistry, University of Toronto and Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia, Toronto, ON, Canada, 6Laboratory Medicine Program, Unviersity Health Network, Toronto, Canada, 7Memorial University of Newfoundland, Faculty of Medicine, Division of Rheumatology, St. John's, Canada, 8University of Toronto, Toronto, ON, Canada

Meeting: ACR Convergence 2024

Keywords: metabolomics, Psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: SpA Including PsA – Treatment Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: There is an unmet need to improve treatments for patients with Psoriatic Arthritis (PsA). Biologic disease-modifying antirheumatic drugs (bDMARDs) such as interleukin-17 inhibitors (IL-17i) are key therapeutics for PsA patients. There is limited knowledge of markers that predict response to treatment. This study aims to identify serum metabolite markers associated with treatment response to IL-17i at baseline and post treatment to improve treatment plan selection and patient outcomes.

Methods:  In this study, 35 patients (18 males, 17 females with swollen joint count mean 1.83, (SD=3.14), tender joint count mean 5.03, (SD=7.14), mean 5.85 (SD=11.91) PASI) were treated with were included. Serum samples were collected at baseline and 3-months post treatment. Patients were classified as responders or non-responders based on clinician evaluations and Disease Activity Index for Psoriatic Arthritis (DAPSA) scores taken pre- and post-treatment. To determine predictive and indicative markers of response to treatment, comparisons were made at baseline and post-treatment between responders vs non responders. Samples were prepared and analysed using solid-phase microextraction coupled to Liquid Chromatography-High Resolution Mass Spectrometry (LC-MS) in negative and positive modes through an untargeted metabolomics approach. Machine learning methods were used to investigate key metabolomic distinctions between responders and non-responders pre- and post treatment. The top features from machine learning models were then tentatively identified.

Results:  When comparing non responders (n = 26) vs responders (n = 9) comparison, LogRegL2 (AUC = 0.966) was the highest-performing model for negative mode data (10 features), while SVM (AUC= 0.970) was the highest-performing model for positive mode data (5 features). Some of the features tentatively identified like O-Propanoyl-D-carnitine; 17-Hydroxyprogesterone; L-Tyrosine are connected to other diseases like type 2 diabetes, rheumatoid arthritis, inflammatory bowel disease, Crohn’s disease, and obesity. Other tentatively identified metabolites included creatinine,  a biomarker for chronic kidney disease. Interestingly, cystine one of the potential metabolites plays a role in the detoxification pathway for dermatophytes.

Conclusion: An untargeted metabolomics approach was employed to uncover potential predictive and indicative markers and of IL17i treatment response in patients with PsA. Potential metabolites belonging to classes like fatty acyls and carboxylic acids and derivatives have been tentatively identified and associated with the PsA serum metabolome and response to bDMARDS like TNFi and IL-17i. Closer examination and validation of the circulating metabolites in PsA patients are ongoing.

Supporting image 1


Disclosures: A. Cave: None; S. Li: None; N. Looby: None; M. Kotiyar: None; I. Jurisica: None; V. Kulasingam: None; P. Rahman: AbbVie, 2, Amgen, 2, Bristol Myers Squibb, 2, Celgene, 2, Eli Lilly, 2, Janssen, 2, 5, 12, Meeting attendance/travel support, Novartis, 2, 5, Pfizer, 2, UCB, 2; V. Chandran: AbbVie/Abbott, 1, 5, AstraZeneca, 12, Spousal employment, Bristol-Myers Squibb(BMS), 1, Eli Lilly, 1, Janssen, 1, Novartis, 1, UCB, 1.

To cite this abstract in AMA style:

Cave A, Li S, Looby N, Kotiyar M, Jurisica I, Kulasingam V, Rahman P, Chandran V. Predictive Potential of Serum Metabolites Associated with Treatment Response to Interleukin -17 Inhibitors in Patients with PsA [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/predictive-potential-of-serum-metabolites-associated-with-treatment-response-to-interleukin-17-inhibitors-in-patients-with-psa/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/predictive-potential-of-serum-metabolites-associated-with-treatment-response-to-interleukin-17-inhibitors-in-patients-with-psa/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology